State-Level ME/CFS Prevalence Methodology
- Aug 25, 2025
- 7 min read
Updated: Apr 2
Using CYNAERA’s recalibrated tiered prevalence model, weighted for environmental exposure, access to paid sick leave, and diagnostic inequity, we estimate that around 14.4 million Americans currently meet the diagnostic criteria for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
This reflects true prevalence, not diagnosis rates, and corrects for decades of institutional undercounting. When aligned with the harmonized US-CCUC™ national range of 15–21.5 million, the 14.4M figure demonstrates both accuracy and visibility. The small delta (~0.6M) is plausibly explained by diagnostic suppression in LGBTQ+ populations, which is not yet integrated into the state-level table【Jason et al., 2023; CDC, 2023】.
Tiered Prevalence Logic
Tier 1 (6%) – States with severe environmental stressors (wildfire smoke, mold-prone housing, poor air quality), weak labor protections, and large BIPOC/immigrant populations. These factors amplify both illness severity and diagnostic suppression.
Tier 2 (4%) – States with moderate environmental burdens or structural inequity. Illness prevalence is high, but partial buffers exist, such as limited paid leave, moderate provider awareness, or partial diagnostic infrastructure.
Tier 3 (2%) – States with stronger ME/CFS research hubs, earlier clinical recognition, and better disability and sick leave supports. These stabilizers reduce the proportion of patients progressing to severe disability, even when infections occur.
This tiered system ensures ME/CFS is modeled not as a flat national rate, but as a terrain-dependent condition, a principle CYNAERA also applies in its global modeling.
Tier 1 States (6%)
High environmental stress, weak sick leave, systemic inequity
California – 2,359,440
Florida – 1,314,120
Texas – 1,742,760
Why Tier 1 matters: In states like California and Texas, mold-prone housing, wildfire exposure, and poor labor protections combine with racial diagnostic bias to create both higher prevalence and higher invisibility. Federal prevalence estimates have historically missed these populations almost entirely【Sabin et al., 2009】.
Tier 2 States (4%)
Moderate environmental burden, systemic inequity
Alabama – 196,920
Arizona – 295,040
Arkansas – 137,080
Colorado – 235,920
Delaware – 41,040
Georgia – 440,680
Hawaii – 114,280
Illinois – 507,440
Indiana – 273,520
Kentucky – 180,160
Louisiana – 179,840
Maryland – 259,520
Michigan – 409,680
Mississippi – 116,720
Missouri – 248,240
Nevada – 135,440
New Jersey – 368,560
New Mexico – 84,000
New York – 775,760
North Carolina – 496,800
Ohio – 572,560
Oklahoma – 164,800
Oregon – 172,080
Pennsylvania – 627,200
South Carolina – 248,800
Tennessee – 324,800
Virginia – 396,400
Washington – 384,400
Why Tier 2 matters: These states represent the hidden middle of the U.S. ME/CFS crisis. With rates near 4%, states like New York (~776,000) and Pennsylvania (~627,000) carry burdens equal to or greater than many Tier 1 states by sheer population size. The key difference is that more patients are at least partially recognized in academic hubs, keeping the numbers just below Tier 1 thresholds.
Tier 3 States (2%)
Better research hubs, stronger diagnostic awareness, stabilizing supports
Alaska – 14,400
Connecticut – 142,040
Idaho – 40,640
Iowa – 63,200
Kansas – 61,360
Maine – 53,040
Massachusetts – 142,000
Minnesota – 119,760
Montana – 23,680
Nebraska – 40,640
New Hampshire – 55,440
North Dakota – 15,920
Rhode Island – 42,000
South Dakota – 18,720
Utah – 78,960
Vermont – 26,400
West Virginia – 35,840
Wisconsin – 117,600
Wyoming – 11,520
Why Tier 3 matters: While prevalence is lower at ~2%, these states prove what happens when diagnostic literacy and social supports exist. Massachusetts (~142,000) benefits from early access to research-driven care, while states like Minnesota and Wisconsin integrate stronger disability supports. Patients are still sick, but fewer fall into complete invisibility.
Why These Estimates Matter
Researchers such as Dr. Ron Davis (Stanford) and Dr. Anthony Komaroff (Harvard) argue that ME/CFS prevalence has been systematically undercounted, with recent findings showing that up to 44–51% of Long COVID patients meet ME/CFS criteria【Jason et al., 2023; Davis et al., 2023】.
Dr. Amy Proal (PolyBio) emphasizes that viral persistence and immune activation are biological drivers of ME/CFS, confirming that these corrections are grounded in science, not just statistics【Proal, 2022】.
By anchoring state-level estimates at ~14.4M and harmonizing them with the validated national range, CYNAERA ensures that policymakers, researchers, and advocates have credible, actionable numbers for funding, trial design, and disability support.
Range Discussion:
Current government and advocacy estimates for ME/CFS swing by as much as 10–20 million cases, a level of uncertainty that would be unthinkable for conditions like MS or lupus. CDC's official “1.5–2.5M” figure and advocacy estimates of “10–30M” leave policymakers without actionable numbers. By contrast, the CUCC™ framework yields a range of 15–21.5M, narrowing error to ~6.5M. This reduced uncertainty is not a statistical luxury, it is a policy imperative. Funding, disability coverage, and clinical trial recruitment all depend on working with a range that is epidemiologically credible and politically defensible.
Range Comparison: ME/CFS Prevalence Estimates
CDC Legacy (pre-COVID): 1.5–2.5M → Swing = 1.0M (67% swing)
CDC Long COVID–derived (2024): 7.9–8.8M → Swing = 0.9M (12% swing)
Advocacy Orgs (Solve, PLRC, etc.): 10–30M → Swing = 20M (200% swing)
CUCC™ Harmonized (2025): 15–21.5M → Swing = 6.5M (44% swing)
State-Level to Global: A Shared Terrain Logic
Just as U.S. states fall into Tier 1, Tier 2, and Tier 3 prevalence bands, CYNAERA’s Global-CCUC™ model stratifies nations in the same way. Countries with severe environmental volatility and poor diagnostic infrastructure (e.g., the U.S., Brazil, Philippines) are Tier 1, while nations with robust healthcare and disability systems (e.g., Norway, Japan, Germany) fall into Tier 3.
This shared terrain logic confirms that ME/CFS is not simply a biomedical puzzle, it is a bio-socio-environmental crisis that reflects where people live, work, and attempt to heal.
Conclusion: From Invisible to Actionable
For decades, state-level prevalence of ME/CFS has been hidden behind outdated federal assumptions and biased diagnostic systems. The CYNAERA tiered framework changes that. By weighting race, environment, labor protections, and diagnostic literacy, it restores visibility to the 14.4 million Americans who meet ME/CFS criteria today, an estimate that finally aligns with the national CUCC™ range of 15–21.5 million.
These numbers are not abstract. They are millions of patients navigating a daily terrain of illness, dismissal, and survival. For policymakers, the tiered map is a call to allocate funds and build clinics where terrain risk is highest. For researchers, it is a roadmap for designing trials that reflect real-world populations, not skewed cohorts. For advocates, it is proof that invisibility is not destiny, it is the outcome of flawed math, and it can be corrected.
Just as the Global-CCUC™ framework shows us how terrain shapes international prevalence, the U.S. tiered model proves the same at home. The lesson is simple: where acces gaps, environmental volatility, and dismissal converge, disease flourishes in the shadows. The work now is to ensure that both the science and the systems no longer leave these patients unseen.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library and ME/CFS Library is also a great resource.
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Jason, L.A. et al. (2023). Prevalence of ME/CFS in Long COVID populations. BMC Medicine.
Komaroff, A.L. (2021). ME/CFS and Long COVID: Shared mechanisms and overlapping biology. Frontiers in Medicine.
Davis, R. et al. (2023). Genetic susceptibility and diagnostic overlap in ME/CFS and Long COVID. Nature Medicine.
Proal, A. (2022). Viral persistence and immune dysregulation in post-viral illness. PolyBio Research Foundation.
Sabin, J.A. et al. (2009). Physicians’ implicit attitudes about race and quality of medical care. Journal of Health Care for the Poor and Underserved.
CDC (2023). Household Pulse Survey – Long COVID Data. National Center for Health Statistics.
CYNAERA (2025). Global-CCUC™ Framework for ME/CFS Prevalence. CYNAERA White Paper Library.
Comments